JP2024156702A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024156702A5 JP2024156702A5 JP2024112292A JP2024112292A JP2024156702A5 JP 2024156702 A5 JP2024156702 A5 JP 2024156702A5 JP 2024112292 A JP2024112292 A JP 2024112292A JP 2024112292 A JP2024112292 A JP 2024112292A JP 2024156702 A5 JP2024156702 A5 JP 2024156702A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- disease
- specific
- individual
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462048742P | 2014-09-10 | 2014-09-10 | |
| US62/048,742 | 2014-09-10 | ||
| JP2020182268A JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2022178874A JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178874A Division JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024156702A JP2024156702A (ja) | 2024-11-06 |
| JP2024156702A5 true JP2024156702A5 (enExample) | 2025-06-17 |
Family
ID=54238541
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513786A Active JP7044551B2 (ja) | 2014-09-10 | 2015-09-10 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2020182268A Active JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2022178874A Active JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2024112292A Pending JP2024156702A (ja) | 2014-09-10 | 2024-07-12 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513786A Active JP7044551B2 (ja) | 2014-09-10 | 2015-09-10 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2020182268A Active JP7175951B2 (ja) | 2014-09-10 | 2020-10-30 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
| JP2022178874A Active JP7592060B2 (ja) | 2014-09-10 | 2022-11-08 | 免疫原性変異体ペプチドスクリーニングプラットフォーム |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10564165B2 (enExample) |
| EP (2) | EP3194970B1 (enExample) |
| JP (4) | JP7044551B2 (enExample) |
| CN (2) | CN113791220A (enExample) |
| AU (3) | AU2015315005B9 (enExample) |
| CA (1) | CA2960834A1 (enExample) |
| WO (1) | WO2016040682A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732131B2 (en) | 2006-02-27 | 2017-08-15 | Calviri, Inc. | Identification and use of novopeptides for the treatment of cancer |
| CN113791220A (zh) | 2014-09-10 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 免疫原性突变体肽筛选平台 |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
| CA3056212A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene Corporation | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
| US11927591B2 (en) | 2016-08-02 | 2024-03-12 | Georgetown University | Methods of identifying novel proteins and antigens in cancer cells |
| US10350280B2 (en) | 2016-08-31 | 2019-07-16 | Medgenome Inc. | Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore |
| JP7155470B2 (ja) * | 2017-03-31 | 2022-10-19 | エーシーティー ジェノミックス （アイピー） カンパニー リミテッド | 免疫原性がん特異的エピトープのためのランク付けシステム |
| JP2020522479A (ja) | 2017-06-02 | 2020-07-30 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ | 個別化された癌ワクチンを作製する方法 |
| US20200219586A1 (en) * | 2017-06-27 | 2020-07-09 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | MHC-1 Genotypes Restricts The Oncogenic Mutational Landscape |
| US12025615B2 (en) | 2017-09-15 | 2024-07-02 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods of classifying response to immunotherapy for cancer |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| EP3759131A4 (en) * | 2018-02-27 | 2021-12-01 | Gritstone bio, Inc. | NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS |
| WO2019173687A1 (en) * | 2018-03-08 | 2019-09-12 | The Trustees Of Indiana University | Constrained de novo sequencing of neo-epitope peptides using tandem mass spectrometry |
| CN108713136B (zh) * | 2018-03-29 | 2020-10-09 | 深圳达闼科技控股有限公司 | 物质检测方法、装置、电子设备及计算机可读存储介质 |
| EP3807320A4 (en) * | 2018-06-12 | 2022-03-23 | BioNTech US Inc. | POLYTHERAPY INCLUDING A VACCINE BASED ON NEO ANTIGENS |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| JP2021534394A (ja) * | 2018-08-14 | 2021-12-09 | ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | 主要組織適合遺伝子複合体に結合されたペプチドを配列決定する単一分子 |
| WO2020101037A1 (ja) * | 2018-11-16 | 2020-05-22 | 株式会社Ｔｎｐパートナーズ | オーダーメイド医療基幹システム |
| BR112021005353A2 (pt) | 2018-11-21 | 2021-06-15 | Nec Corporation | método e sistema de direcionamento de epitopos para imunoterapia baseada em neoantígeno |
| WO2021067550A1 (en) | 2019-10-02 | 2021-04-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions for identifying neoantigens for use in treating and preventing cancer |
| CN112769742B (zh) * | 2019-11-06 | 2024-06-14 | 电科云(北京)科技有限公司 | Spdz系列协议中的消息验证方法、装置及存储介质 |
| CN111863130A (zh) * | 2020-04-07 | 2020-10-30 | 至本医疗科技（上海）有限公司 | 肿瘤免疫治疗预后标志物的筛选方法及应用 |
| WO2025101535A1 (en) * | 2023-11-07 | 2025-05-15 | Seer, Inc. | Biomolecule cleanup methods, kits, and systems |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US47404A (en) | 1865-04-25 | Improvement in sawing-machines | ||
| US1100474A (en) | 1914-04-01 | 1914-06-16 | Alfred J Croft | Hand-tool. |
| US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| EP1876241A3 (en) | 1996-01-11 | 2008-07-30 | Corixa Corporation | Compositions and methods for the treatment and diagnosis of breast cancer |
| TR200001253T2 (tr) | 1997-11-06 | 2000-11-21 | Roche Diagnostics Gmbh | Tümöre özel antijenler |
| EP1117430A1 (en) | 1998-10-05 | 2001-07-25 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
| EP1257961A1 (en) * | 1999-11-12 | 2002-11-20 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
| EP1261704B1 (en) | 1999-11-30 | 2009-07-01 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| US20050221350A1 (en) | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| WO2003106692A2 (en) | 2002-06-13 | 2003-12-24 | Merck Patent Gmbh | Methods for the identification of all-antigens and their use for cancer therapy and transplantation |
| DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
| EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
| JP2009532664A (ja) | 2006-02-27 | 2009-09-10 | アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ | 癌の治療のためのノボペプチドの同定および使用 |
| DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
| US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
| MX2011005691A (es) | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| EP2569633B1 (en) | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| WO2014012051A1 (en) | 2012-07-12 | 2014-01-16 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| EP3417874B1 (en) | 2012-11-28 | 2024-09-11 | BioNTech SE | Individualized vaccines for cancer |
| EP2983702A2 (en) | 2013-04-07 | 2016-02-17 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
| WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
| WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
| CN113791220A (zh) | 2014-09-10 | 2021-12-14 | 豪夫迈·罗氏有限公司 | 免疫原性突变体肽筛选平台 |
| WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
-
2015
- 2015-09-10 CN CN202110939479.5A patent/CN113791220A/zh active Pending
- 2015-09-10 JP JP2017513786A patent/JP7044551B2/ja active Active
- 2015-09-10 WO PCT/US2015/049491 patent/WO2016040682A1/en not_active Ceased
- 2015-09-10 AU AU2015315005A patent/AU2015315005B9/en active Active
- 2015-09-10 CA CA2960834A patent/CA2960834A1/en active Pending
- 2015-09-10 CN CN201580059468.0A patent/CN107076762B/zh active Active
- 2015-09-10 EP EP15772084.8A patent/EP3194970B1/en active Active
- 2015-09-10 EP EP21187832.7A patent/EP3998481A1/en active Pending
- 2015-09-10 US US14/850,864 patent/US10564165B2/en active Active
-
2020
- 2020-01-03 US US16/733,988 patent/US12372533B2/en active Active
- 2020-10-30 JP JP2020182268A patent/JP7175951B2/ja active Active
-
2021
- 2021-10-13 AU AU2021250887A patent/AU2021250887B2/en active Active
-
2022
- 2022-11-08 JP JP2022178874A patent/JP7592060B2/ja active Active
-
2024
- 2024-07-02 US US18/762,502 patent/US20240418731A1/en active Pending
- 2024-07-12 JP JP2024112292A patent/JP2024156702A/ja active Pending
-
2025
- 2025-04-14 AU AU2025202619A patent/AU2025202619A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024156702A5 (enExample) | ||
| JP7592060B2 (ja) | 免疫原性変異体ペプチドスクリーニングプラットフォーム | |
| JP2017534257A5 (enExample) | ||
| CN1072719C (zh) | 可分离的编码肿瘤排斥抗原前体的核酸序列 | |
| Lucas et al. | A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells | |
| JP2021501572A5 (enExample) | ||
| JP2009506762A5 (enExample) | ||
| CN111328420B (zh) | 用于预防和治疗微卫星不稳定(msi)癌症的基于共有肿瘤新抗原的通用疫苗 | |
| JP2006515749A5 (enExample) | ||
| JP2017524337A5 (enExample) | ||
| JP2006526414A5 (enExample) | ||
| JP2005511037A5 (enExample) | ||
| EP4623996A3 (en) | COMPOSITIONS AND METHODS FOR IDENTIFYING TUMOR-SPECIFIC NEOANTIGENS | |
| WO2015058780A1 (en) | Method and kit for determining whether a subject shows an immune response | |
| HK1043729B (en) | Use of CASB616 polypeptide and polynucleotide for cancer treatment | |
| JP2004502408A5 (enExample) | ||
| CN106029699A (zh) | Wt1抗原性多肽和含有该多肽的抗肿瘤剂 | |
| JP2021508313A5 (enExample) | ||
| PL209127B1 (pl) | Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka | |
| JP2020524145A (ja) | 細菌性ワクチン | |
| DK200601181A (da) | Fiskevaccine | |
| JP2004537284A5 (enExample) | ||
| JP2023528220A5 (enExample) | ||
| CN1354668A (zh) | 分离的与hla－b35分子结合的肽 | |
| JP2022533861A5 (enExample) |